promotion of expensive device for off-label uses not shown likely to deceive

Zeltiq Aesthetics, Inc. v. BTL Industries, Inc., No. 13–cv–05473, 2014 WL 1245222 (N.D. Cal. Mar. 25, 2014) (magistrate judge)

Zeltiq sued defendants for allegedly falsely advertising that a BTL medical device was FDA approved for fat reduction and body contouring.  The court denied a preliminary injunction.

Class I and II medical devices don’t need premarket approval, only premarket notification to the FDA.  If the FDA deems a Class II device to be “substantially equivalent” to a preexisting cleared device, it can be marketed without further regulatory scrutiny.

Zeltiq sells a medical device known as CoolSculpting, which is intended to cause fat cell elimination without causing scar tissue or damage to the skin, nerves or surrounding tissue. It’s been FDA-cleared for cold-assisted lipolysis of the flank and the abdomen.  Zeltiq alleged that it obtained clearance by submitting clinical studies and other data, because clearance of a device for treatment of body fat lends instant and substantial credibility.  As a result, CoolSculpting allegedly became the leading noninvasive fat reduction medical device, with huge sales jumps in a year.

BTL submitted a notice of intent to market the BTL Elite, asking for FDA clearance to market the device for applying heat to body tissues for pain relief, treating muscle spasm, increasing range of motion for joints, and increasing blood flow to tissues.  The FDA cleared the BTL Elite for these uses. Zeltiq alleged that BTL was unlawfully marketing a device called the Vanquish—the BTL Elite by another name—for fat reduction and body contouring. Both parties sell to doctors, not patients.

Zeltiq alleged that BTL didn’t promote Vanquish at all for treating muscle aches and spasms, but instead touted it for fat reduction while touting it as “FDA-cleared,” attempting to mislead doctors into believing that Vanquish was FDA-approved for fat reduction.

BTL didn’t dispute that it promoted Vanquish for fat reduction, an admittedly off-label use, nor that it only intended to do so (and not for muscle aches).  Its trademark registration describes Vanquish as a “[b]ody treatment device using heating and cooling for fat cell reduction.”  However, defendants argued that they’d stopped promoting Vanquish in the US for off-label use, and that they never represented that Vanquish had FDA clearance for fat reduction/body contouring.

Judge for yourself: in October 2013, as a sponsor of the annual meeting for the American Society for Dermatologic Surgery, BTL invited doctors to a private demonstration by stating: “Join us for a private demonstration of a newly FDA cleared technology … The only complete solution for non-invasive body shaping.”  Unless what comes between the dots is a discussion of the clearance for ache treatment (which BTL admitted wasn’t promoted) and clarification of what the FDA clearance was for, this is classic implicature; any linguistically competent English speaker should’ve taken away the implication that the clearance was for fat reduction. 

BTL also promoted fat reduction to end consumers, e.g., the technology “is proven to destroy fat cells.”  In addition, BTL allegedly recruited doctors to promote Vanquish to patients, and BTL didn’t dispute its involvement with vanquishfat.com (though it did dispute its involvement with other sources that promoted Vanquish to consumers for fat reduction). On that website, a doctor stated that he had “heard about a new, fat zipping device that’s about to receive FDA approval,” and the same doctor created a “Vanquish Fat” Facebook page and claimed that “Vanquish Melts Fat With No Pain.”

Also, BTL argued that in 2014, it hadn’t done anything in the US to promote Vanquish for fat reduction.  In rebuttal, Zeltiq submitted evidence that BTL planned to exhibit at two shows in February and April, displaying the Vanquish device “obscurely described as delivering ‘sub-cutaneous heating for body treatment based on induced apoptosis using a contract-free operator-monitored clinical approach.”

BTL has both a US website and a non-US website, bltvanquish.com and bltvanquish.com/en/vanquish.html respectively.  (Um, that looks an awful lot like one website.)  BTL argued that it only controlled the content of the US website, and the content of the non-US website was controlled overseas by a related company and directed at a worldwide audience. Only the non-US website presently promotes Vanquish for fat reduction explicitly, though the US site allegedly used to do so by showing a video from a Texas doctor who said it “shrinks fat cells,” and quoting a number of other U.S. doctors extolling its fat reduction benefits.   

BTL modified the US website after this lawsuit was filed, and BTL said that it sought out help for training about its marketing obligations.  Now, the US website describes Vanquish as “a revolutionary selective radiofrequency system” that “delivers a non-invasive solution with unparalleled efficacy” and “is the first and only non-invasive body treatment finally integrating all the most desired features.” The website states that “Vanquish is FDA cleared for deep tissue heating.”  Fine print describes its specific intended FDA-cleared indications.  (Wow, that really has the feeling of code.  How the heck would a consumer know what Vanquish was for? And why would you only describe what it was really for in fine print, unless you expected that consumers would already have something in mind, or would click around until they found real information, perhaps on the non-US part of the site?)  The website also said that it was for US medical professionals only, and wasn’t cleared for treating adipose tissue (fat).

Zeltiq argued that despite the purported two-site solution, the non-US website was actually intended to promote to the US.  For example, BTL sent invitations to doctors to attend open houses, and only listed the address for the non-United States website on the invitation.  “Moreover, until recently, the largest and boldest text on the United States website was a link in the middle of the page that stated, ‘Go to Non-US Website.’”  In fact, the US website contained hardly any information—most of it is quoted above.  The non-US site promotes Vanquish for fat reduction, including a page that links to magazine articles and videos quoting United States doctors who promote Vanquish for fat reduction.  The “international” website also used to include a page for seminars for doctors, listing five conferences in the US.  A version listing conferences in 2014 showed conferences planned both inside and outside the US.

A new US-targeted website, which BTL denied any control over, promoted Vanquish for fat removal, including links to two video clips—allegedly the same clips that were deleted from BTL’s original website.  In one, a doctor appears on Fox News. When he’s asked whether Vanquish is safe, he responds:

This is exceptionally safe. The FDA basically is there to provide safety, it is not so much there to provide efficacy. So when they do these FDA approval studies, the number one, two and three thing they are looking at is safety, and this is exceptionally safe. They—even in the animal models, they looked at every part of the animal to ensure that there was no damage to anything other than the fat.

Zeltiq, understandably, argued that this was misleading, suggesting that the FDA approved Vanquish for the purpose for which it was being promoted.  (Query: after Lexmark, can Zeltiq sue individual doctors making claims about Vanquish?)

But what do doctors think? Both sides submitted declarations from doctors. Zeltiq’s declarant said that doctors make off-label uses, but that they generally only develop after doctors have experience with a new device for its approved use, and that information about a new device is generally scant.  She concluded that when a manufacturer promotes a new device in the early stages after device is launched, physicians would presume that the new device has been approved by the FDA for the promoted use.   BTL submitted declarations from two other doctors.  One noted that both parties’ devices cost approximately $80,000 to $90,000, and both said that before they bought the Vanquish device they were made aware of the scope and limits of FDA clearance.

BTL argued preemption.  The court found this a serious question, but better dealt with on a full record.  For one thing, the core claim—a false or misleading representation of clearance for fat reduction—wasn’t preempted regardless. Also, since BTL didn’t dispute that it promoted Vanquish for a non-FDA-cleared use, interpretation of FDA rules wouldn’t be required to decide the false advertising claim.

However, the court concluded, Zeltiq didn’t show literal falsity.  Instead, the “newly FDA cleared technology” invitation wasn’t literally false because Vanquish was FDA cleared, even if not for body shaping.  (Ugh.  That’s sophistry, which is the point of having a doctrine of falsity by necessary implication.)  Nor does the current website contain literal falsity. Zeltiq argued falsity by necessary implication, but the court didn’t buy it, stating without further explanation that none of the identified statements necessarily implied FDA clearance for fat reduction.  Half-truths aren’t literally false.

Zeltiq did show that BTL’s promotions were potentially misleading, and its use of FDA clearance as a selling point in promotional materials was evidence of materiality. But Zeltiq didn’t show that any doctors had been fooled. “At best, Zeltiq’s evidence shows that physicians in general presume the Vanquish device is FDA cleared for fat reduction because it was marketed for that use in the early stages after its launch.” This evidence was too general—it didn’t show that actual purchasers believed the Vanquish was FDA cleared.  BTL’s evidence suggested that “at least one group of physicians decides to purchase such an expensive medical device only after fully evaluating the device’s efficacy and safety for patients and understanding the official FDA clearances.” 

In light of the device’s high cost and limitation to doctor-purchasers, Zeltiq wasn’t likely to prove deception. Still, there were serious questions going to the merits.

Zeltiq brought a serpate claim under the California UCL’s “unlawful” prong.  While the UCL prohibits the sale of an uncleared device, the Vanquish was cleared, and the statute wasn’t use-specific. Zeltiq also argued that the Vanquish was misbranded because its labeling fails to include “adequate directions for use” in fat reduction procedures. “In light of the fact the FDCA regulations require instructions to be catered to ‘the purposes for which [the device] is intended,; Zeltiq raises an interesting argument.”  But the “labeling” was the targeted source of misbranding, and the operator’s manual included instructions detailing the FDA-cleared uses and providing directions for such uses.  Zeltiq didn’t convince the court that misbranding can come from overall promotional practices, though it did raise serious questions going to the merits.

But the balance of hardships didn’t tip sharply in Zeltiq’s favor.  Zeltiq could suffer without an injunction, losing its unique place in the market.  But BTL would endure hardship from an injunction, which as Zeltiq proposed would require delinking the US and non-US websites and providing written notification to every doctor who bought the Vanquish that it’s not FDA-cleared for fat reduction. Zeltiq also wanted to bar BTL from selling Vanquish for non-cleared uses, but doctors have the right to make off-label uses.

Also, Zeltiq didn’t show irreparable injury. Though lost market share can be irreparable harm, Zeltiq didn’t show actual lost market share. Zeltiq argued that it could show likely irreparable injury by showing that the parties competed and that there was a logical causal connection between the false advertising and its own sales position.  But the court thought that this wasn’t enough in light of Winter, which held that a showing of irreparable injury is always required.  “Merely showing that the parties are competitors and that there is a logical connection between the false advertising and the plaintiff’s sales may be sufficient to show a possibility of irreparable harm, but is insufficient to show a likelihood of irreparable harm without additional evidence.”  (Again, I wonder when if ever this kind of reasoning will hit trademark.)
Posted in http://schemas.google.com/blogger/2008/kind#post | Leave a comment

Must false advertising claims always be pled with particularity?

LT Int’l Ltd. v. Shuffle Master, Inc., 2014 WL 1248270, No. 2:12–cv–1216 (D. Nev. March 26, 2014)

Here, the court disapproved a five-page complaint, finding that the false advertising and related claims sounded in fraud but didn’t satisfy Rule 9(b), and dismissed with leave to amend. LT sells gaming products, including an electronic interface that allows gamblers at a casino table to simultaneously place bets at other tables.  LT’s direct competitor Shuffle Master allegedly disparaged LT’s products and services.

The court found that LT was bringing a Lanham Act false advertising claim.  While neither fraud nor mistake is an element of a Lanham Act false advertising claim, and thus it doesn’t inherently trigger Rule 9(b), in the 9th Circuit Rule 9(b) is triggered when the complaint uses the language of fraudulent conduct.  (Why? This has never been adequately explained to me.)  So once a complaint uses the word “misrepresentation,” that’s a species of fraud. Only the fraudulent conduct allegations have to satisfy Rule 9(b), and if they’re inadequate they should be stripped.  Comment: See, this is what’s really weird to me about how this principle is applied (well, this and why trademark plaintiffs never run into this problem).  The difference between “intentionally false” and “unintentionally false” is intent, right?  And intent and knowledge may be averred generally even under Rule 9(b), correct?  So why does alleging intent convert a claim based purely on falsity—where intent isn’t required to prevail under the statute—to a claim sounding in fraud?  What am I missing?

Anyway, the fraud-based allegations were conclusory, referring to “an international campaign of disparagement,” claiming “misrepresentations regarding Plaintiff’s business and products, including Plaintiff’s LT Game Live Multi–Table System, at international trade shows, including at the G2E gaming trade show in May, 2012 in Macau, and directly and indirectly to Plaintiff’s current and prospective customers in the gaming and casino industry.”  LT identified two customers as among those to whom the misrepresentations had been made.  Even if this constituted the who, where, and when, it didn’t explain how the statements were made, and LT didn’t allege the factual content of any statement, even though LT was required to allege with particularity “what is false or misleading about the purportedly fraudulent statement, and why it is false.” This also disposed of the Nevada and Macao unfair competition claims, though LT did plead a plausible claim for tortious interference with prospective business and contractual relations.
Posted in http://schemas.google.com/blogger/2008/kind#post, procedure | Leave a comment

A mocking Snickers ad and Google v. Garcia

Sociological Images covers a Snickers ad that apparently shows real women responding to supportive, nonsexist comments from construction workers. “The first thing women do is get uncomfortable, revealing how a lifetime of experience makes them cringe at the prospect of a man yelling at them.  But, as women realize what’s going on, they’re obviously delighted.  They love the idea of getting support and respect instead of harassment from strange men. This last woman actually places her hand on her heart and mouths ‘thank you’ to the guys. And then the commercial ends and it’s all yanked back in the most disgusting way.” Tagline: “You’re not you when you’re hungry.” SocImages: “I wonder, when the producers approached them to get their permission to be used on film, did they tell them how the commercial would end? I suspect not. And, if not, I bet seeing the commercial would feel like a betrayal.”

What result in the 9th Circuit, if one of the women sues for infringement based on fraudulent inducement of her participation?

Posted in http://schemas.google.com/blogger/2008/kind#post | Leave a comment

Organic v. natural

Via an eagle-eyed student, a great video on misleading “natural” claims.  Note that the organization promotes organic products—is it subject to Lanham Act claims by a producer of “natural” foods?

Posted in advertising, consumer protection, http://schemas.google.com/blogger/2008/kind#post | Leave a comment

Relevant to my interests: Jensen Ackles and the right of publicity

It is a truth universally acknowledged that Jensen Ackles is a very attractive man.  So attractive that he tends to show up in a variety of advertising contexts that, I suspect, his agent does not know about.  Consider this example, apparently based on fan art, according to the poster appearing at a Rite Aid (but sadly, not near me):

More examples at the link.  So we have fan artist, photographer, and celebrity rights potentially implicated.  I wonder what kind of representations the display provider made to Rite Aid.
Posted in fanworks, http://schemas.google.com/blogger/2008/kind#post, right of publicity, trademark | Leave a comment

Taco Bell endorsed by Ronald McDonalds

H/T Deborah Gerhardt. Via AdAge:

Ronald McDonald loves Taco Bell’s breakfast. That’s what Taco Bell is saying in its campaign introducing its biggest menu rollout yet. The Mexican food chain located a slew of actual Ronald McDonalds and got them to appear in new ads for its breakfast launch proclaiming their love for Taco Bell’s new breakfast menu.

You might wonder what Taco Bell was thinking.  I think it might’ve been thinking Marriott Corp. v. Ramada Inc., 826 F.Supp. 726 (S.D.N.Y. 1993) (finding that ads featuring actual people Frank and Cindy Marriott and Donald and Sally Hyatt, and stating “Why the Marriotts [Hyatts] Stay at Renaissance,” didn’t violate the Lanham Act).  There, the court said:

It is obvious from even a cursory reading that they are clearly tongue-in-cheek. I cannot see that any reasonable person would be misled—even absent the disclaimer—into believing that the Marriotts or Hyatts featured in the advertisements are in any way related to plaintiffs Marriott Corporation, J.W. Marriott, Jr. or Hyatt Corporation or that the Renaissance Hotels have their “origin” in or their “sponsorship[] or approval” from those corporations. Accordingly, there is no “likelihood of confusion”, and plaintiffs’ Lanham Act claims must be dismissed as a matter of law.

Posted in trademark | Leave a comment

use of an established mark as false advertising

Topek, LLC v. W.H. Silverstein, Inc., No. 12–cv–494, 2014 WL 1124311, 2014 DNH 060 (D.N.H. Mar. 20, 2014)

This colorful business dispute caught my eye because “false advertising through use of a trademark” cases are so rare, and this opinion shows why—courts are often unwilling to regulate use of a mark through false advertising law.

Topek presently has a lot, if not all, of the assets of Yankee Barn Homes, “a nationally-recognized builder of custom-designed post and beam homes” founded in 1969.  In 2011, it was unable to pay its creditors; its debt to its primary lender was secured by security interests in virtually all of its assets, including its “intellectual property, trade names, design templates, and goodwill” as well as its real property.  Shortly after Yankee began experiencing difficulties, Silverstein contacted it, and they signed a letter of intent “essentially ceding control of Yankee to Silverstein.” The lender learned of the proposal and refused to approve it, as was apparently its right under its security instruments.  Yankee and Silverstein moved forward anyway; Silverstein began integrating its operations with Yankee’s and began holding itself out to the public as Yankee Barn Homes.

The lender fought back, filing suit against Silverstein.  Yankee apparently realized that it couldn’t actually follow through on its deal without the lender’s approval, and conveyed to the lender all or virtually all of its assets.  The lender then conveyed the same assets, including all of Yankee’s general intangibles such as “copyrights, trademarks, and trade names, including the name Yankee Barn Homes,” as well as its existing inventory, machinery, manufacturing equipment, customer lists, computer records, phone numbers, and ICC certifications—to Topek.  Topek re-opened Yankee’s facility and rehired many of Yankee’s former employees.

Soon thereafter, “Topek concluded that despite a state court order directing Silverstein to stop doing so, Silverstein continued to exercise (or attempt to exercise) control over former assets of Yankee and, in so doing, was interfering with Topek’s ownership of those assets.” It intervened in the ongoing lender-Silverstein litigation.  The state court in that case found that Yankee conveyed all its real and personal property to the lender, and that the lender conveyed all fixed assets to Topek.  However, Silverstein retained the phone numbers from the former Yankee; represented itself to outside parties as “Yankee Barn Homes”; used Yankee certifications; and  interfered with Topek’s Facebook page by claiming copyright infringement of photos used by Topek of Yankee Barn Homes.  The state court, finding likely confusion and irreparable harm, enjoined Silverstein “from (A) representing to anyone that [Silverstein] has purchased Yankee Barn Homes or has any authority to act on behalf of Yankee Barn Homes; and (B) from using or exerting any control over property owned by Yankee Barn Homes, including, but not limited to, the Yankee Barn Home website.”  

The present litigation mostly concerned Topek’s infringement claims.  I will only discuss Silverstein’s motion for a preliminary injunction against Topek’s allegedly false advertising.  Silverstein argued that, while Topek may have bought Yankee’s assets, it didn’t buy the company by acquiring the stock, and therefore wasn’t a successor in interest. Thus, it wasn’t entitled to “hold itself out to the public as ‘Yankee Barn Homes,’ or say that it has been in business since 1969, or claim that it has built award-winning homes throughout the country, or display pictures of homes that it never actually built, or display testimonials from clients who purchased their homes from what Silverstein considers to be the ‘true’ Yankee Barn Homes.”

The court quickly distinguished  Paper Thermometer Co. v. Murray, 2012 WL 194369, 2012 DNH 017 (D.N.H. Jan. 23, 2012), a reverse passing off case involving a defendant who purchased plaintiff’s goods, re-labeled them, represented to the public that it (rather than plaintiff) had engineered and manufactured them, and then sold those products as its own.  Topek argued that its purchase of Yankee’s assets resulted in a “de facto merger,” reasoning that if Topek could be liable for Yankee’s financial obligations, it necessarily can hold itself out to the public as Yankee.

The court found this unpersuasive too; the cases about successor liability weren’t really on point to a question about what name Topek could sell under, or whether it could “claim to manufacture the same high-quality homes today that Yankee Barn produced for many years.”

Fortunately, the court found guidance from Callman on Unfair Competition.  Callman says that it’s

patently misleading to advertise a false date of establishment or to suggest, without warrant, that the reputation of a newly established business is well-known to the public. Reference to an early date of establishment suggests that the business is an experienced, firmly established, successful and reliable concern. Therefore, the dispositive question in any case is whether the business enterprise, as a unit, including all its human elements and its corporeal and incorporeal values, has continued, substantially unchanged, since its inception…..

Many status changes don’t break continuity.  These include “its development from a small craft shop to a big industrial unit; a change in its legal form, e.g., from individual ownership to a partnership or corporation; a change of firm name or trademark; a change of ownership; expansion to other lines of business; bankruptcy; or the transfer of the old business to a new corporation.” Retention of firm name or trademark also evidences continuity.  “Such continuity, however, may be broken by the removal of the business to another country, by its conversion to an entirely different product line, or by its division into several parts transferred to different successors.”

Silverstein didn’t allege any factors indicating a break in business continuity, and several factors suggesting such continuity were present.  Topek bought all or virtually all of Yankee’s assets, including domain names, copyrights, trademarks and service marks, and goodwill. And it operated the same manufacturing facility from which Yankee operated since 1972, using much of Yankee’s former workforce.  Since neither party adequately addressed the relevant issues, and since Silverstein bore the burden, the motion for preliminary injunction was denied.
Posted in http://schemas.google.com/blogger/2008/kind#post, trademark | Leave a comment

We all stand: Static Control can sue

Lexmark International, Inc. v. Static Control Components, Inc., No. 12–873 (March 25, 2014)

Justice Scalia, writing for a unanimous Court, affirmed the Sixth Circuit, in the process articulating a new standard: “To invoke the Lanham Act’s cause of action for false advertising, a plaintiff must plead (and ultimately prove) an injury to a commercial interest in sales or business reputation proximately caused by the defendant’s misrepresentations.”

I’m not surprised that the result of the Court taking the case was a new articulation of the standard; it’s the kind of thing only the Supreme Court can do. Like it or not, the Supreme Court just has a different view of cases than district or appellate courts, and can make very big moves even in statutory interpretation. (Side note: I literally used to think that this day would never come.)

This opinion bears some similarities to another Lanham Act Scalia opinion, Wal-Mart v. Samara Bros., also for a unanimous Court, also presenting itself as simple statutory interpretation, also adopting a standard for which no party advocated. In Wal-Mart, the new rule was designed to limit the post-Taco Cabana flood of unmeritorious claims. Here, the new standard could mean that more plaintiffs get past the pleading stage, though it remains to be seen whether the Second Circuit in particular will read this as a signal to cut back on its own “reasonable interest” results and whether lower courts will read Iqbal/Twombly aggressively to achieve the same results as Conte Bros.-type tests through proximate causation rulings. Also, it remains to be seen whether courts will apply this reasoning, which speaks in terms of §43(a) generally and not §43(a)(1)(B), to trademark cases and require plaintiffs to allege proximate causation of their claimed harms.

Brief reminder: Lexmark makes laser printers and toner cartridges. Remanufacturers refill used Lexmark cartridges and sell them; Lexmark has tried various means to stop this, including a microchip designed to disable empty cartridges until replaced by Lexmark, as part of its “Prebate” line. Static Control isn’t a remanufacturer, but it’s the market leader in selling cartridge components, including chips that can be used to defeat Lexmark’s scheme. Lots of litigation ensued; here we consider only Static Control’s false advertising counterclaim.

Section 43(a) “creates two distinct bases of liability,” false association and false advertising. Static Control alleged the latter, with two types of claims: (1) Lexmark purposely misled users to believe that they were legally bound by Lexmark’s Prebate terms and obliged to return cartridges to Lexmark after one use. (2) Lexmark sent letters to most remanufacturers falsely advising them that it was illegal to sell refurbished Prebate cartridges. This allegedly was a misrepresentation of “the nature, characteristics, and qualities” of both its own products and Static Control’s products. In a footnote, the Court noted that Lexmark argued that this wasn’t “commercial advertising or promotion,” but that question was not before the Court. (As the law professors’ amicus brief I worked on noted, at least one element of the standard Gordon & Breach test for commercial advertising or promotion will quickly need revisiting—the part that requires that the plaintiff be in commercial competition with the defendant; if that sticks, then all this ink spilled on standing will be irrelevant.)

The Court first makes its (Scalia’s) displeasure with the concept of “prudential standing” known. The label is misleading. Article III limits federal courts’ jurisdiction to cases and controversies, so there’s an “irreducible constitutional minimum of standing.” That is a concrete and particularized injury in fact fairly traceable to the defendant’s action, likely to be redressed by a favorable decision. Static Control concededly had Article III standing based on its allegations of lost sales and damage to its business reputation. The idea of nonetheless refusing to decide a case on prudential grounds is in tension with the Court’s statement that “a federal court’s ‘obligation’ to hear and decide” cases within its jurisdiction “is ‘virtually unflagging.’” However, the Court has also used the language of prudential standing. But really, what the Court was properly doing in cases such as Associated General Contractors (the antitrust case from which Conte Bros. derived its Lanham Act standing test) was statutory interpretation of the scope of the remedy created by the underlying statute. Static Control argued that prudential standing should be measured by the “zone of interests” test, and though the Court has used the language of prudential standing in the past, zone of interests isn’t really a prudential test either. Instead, whether a plaintiff is within a statute’s zone of interest “is an issue that requires us to determine, using traditional tools of statutory interpretation, whether a legislatively conferred cause of action encompasses a particular plaintiff ’s claim.” So we ask whether Static Control falls within the class of plaintiffs Congress authorized to sue under §43(a). “Just as a court cannot apply its independent policy judgment to recognize a cause of action that Congress has denied, it cannot limit a cause of action that Congress has created merely because ‘prudence’ dictates.” This inquiry shouldn’t really be labeled “statutory standing” either, since the absence of a valid cause of action doesn’t implicate subject matter jurisdiction.

We can’t read the statute’s reference to “any person who believes that he or she is likely to be damaged” by a defendant’s false advertising literally, since that would allow anyone who satisfied Article III to sue, and we’re sure Congress didn’t mean that, given zone of interests analysis and proximate causation as a background principle.

Zone of interests: plaintiffs can only sue if their interests fall within the zone protected by the law under which they’re trying to sue. This is a background rule of general application, no matter what.  The breadth of the zone varies according to the statute at issue. Fortunately, identifying the Lanham Act’s zone of interests is easy, because of the “unusual, and extraordinarily helpful,” detailed statement of the statute’s purposes in §1127:

The intent of this chapter is to regulate commerce within the control of Congress by making actionable the deceptive and misleading use of marks in such commerce; to protect registered marks used in such commerce from interference by State, or territorial legislation; to protect persons engaged in such commerce against unfair competition; to prevent fraud and deception in such commerce by the use of reproductions, copies, counterfeits, or colorable imitations of registered marks; and to provide rights and remedies stipulated by treaties and conventions respecting trademarks, trade names, and unfair competitionentered into between the United States and foreign nations.

Mostly these purposes relate to false association, and a typical false-advertising case implicates only the goal of “protect[ing] persons engaged in [commerce within the control of Congress] against unfair competition.”  Unfair competition was a “plastic” concept in common law, but “was understood” (nice passive voice!) to cover “injuries to business reputation and present and future sales.” (Citing the YLJ in 1929.)  Thus, to come within §43(a)’s zone of interests, a plaintiff “must allege an injury to a commercial interest in reputation or sales.” Consumers, including business consumers, may have injuries in fact, but can’t bring Lanham Act claims.

Next, we presume that a statutory cause of action is “limited to plaintiffs whose injuries are proximately caused by violations of the statute.”  Reading a proximate cause requirement into §43(a) is therefore also appropriate.  Proximate cause can be tricky, but the basic question is “whether the harm alleged has a sufficiently close connection to the conduct the statute prohibits.”  Harm that’s too remote isn’t actionable, and that usually includes harm derivative of “misfortunes visited upon a third person by the defendant’s acts.” True, “all commercial injuries from false advertising are derivative of those suffered by consumers who are deceived by the advertising.” But because the Lanham Act allows only those who are injured commercially to sue, that intervening step isn’t fatal to showing proximate cause: a plaintiff can be directly injured (for our purposes) by a misrepresentation even when a third party was the one who relied on the misrepresentation.  (Hey, this is an argument for a reliance requirement in trademark as well as false advertising: without consumer reliance of some sort, the plaintiff can’t have been injured!)
As a result, a §43(a) plaintiff “ordinarily must show economic or reputational injury flowing directly from the deception wrought by the defendant’s advertising; and that that occurs when deception of consumers causes them to withhold trade from the plaintiff.”  Ordinarily, that won’t cover injuries to a fellow commercial actor that then hurt the plaintiff—a competitor forced out of business by false advertising can sue, but not the landlord or others who suffer from the competitor’s “inability to meet [its] financial obligations.”  In a footnote, the Court emphasized that Iqbal/Twomblyrequire proximate cause to be adequately alleged in the complaint.

Lexmark argued that the antitrust-based test of Conte Bros. was the way to implement these principles, or that only competitors should be able to sue. Some amici argued for the reasonable interest test instead.  None of these tests was meritless, but no. “[A] direct application of the zone-of-interests test and the proximate-cause requirement supplies the relevant limits on who may sue.”

Why not Conte Bros.? That test had five factors: (1) Is the plaintiff’s injury of a type that Congress sought to redress in providing a private remedy? (2) The directness or indirectness of the asserted injury. (3) The proximity or remoteness of the party to the alleged injurious conduct. (4) The speculativeness of the damages claim. (5) The risk of duplicative damages or complexity in apportioning damages.  While this approach “reflects a commendable effort to give content to an otherwise nebulous inquiry,” it’s still not quite right.  (1) seems to be about the zone of interests, and (2) and (3) relate, redundantly, to proximate causation.  But these aren’t factors to be weighed; they’re requirements to be met in every case. 

And (4) and (5) really go off the rails.  Though difficulty of ascertaining damages caused by a remote injury is one reason we have a proximate cause requirement, difficulty in ascertaining and apportioning damages isn’t “an independent basis for denying standing where it is adequately alleged that a defendant’s conduct has proximately injured an interest of the plaintiff’s that the statute protects.” Even when losses aren’t sufficiently quantifiable for damages, injunctive relief or disgorgement of defendant’s profits may still be available.  “Finally, experience has shown that the Conte Bros. approach, like other open-ended balancing tests, can yield unpredictable and at times arbitrary results. See, e.g., Tushnet, Running the Gamut from A to B: Federal Trademark and False Advertising Law, 159 U. Pa. L. Rev. 1305, 1376–1379 (2011).”

The direct competition test provided a bright line, but only at the expense of distorting the statutory language.  A noncompetitor would have a harder time establishing proximate cause, but a blanket rule would read too much into the phrase “unfair competition,” which—by the time the Lanham Act was adopted—“was understood not to be limited to actions between competitors.” “One leading authority in the field wrote that ‘there need be no competition in unfair competition,’ just as ‘[t]here is no soda in soda water, no grapes in grape fruit, no bread in bread fruit, and a clothes horse is not a horse but is good enough to hang things on.’”

The reasonable interest test was vague, and could be understood to require only Article III standing.  Courts were tired of grappling with it.  Also, the relevant question isn’t whether the plaintiff’s interest is reasonable, but whether the Lanham Act protects that interest; likewise, it’s not whether there’s a reasonable basis for the plaintiff’s claim of harm, but whether there is proximate cause.  Thus, zone of interests plus proximate cause provides clearer and more accurate guidance.

Applying these principles to the present case, Static Control was within the zone of interests protected by Congress.  Its alleged injuries, “lost sales and damage to its business reputation” were injuries to “precisely the sorts of commercial interests the Act protects.” And it sufficiently alleged proximate cause.  Though sales diversion from a competitor might be the paradigmatic direct injury, it’s not the only kind.  First, Static Control alleged that Lexmark disparaged it by asserting that its business was illegal.  “When a defendant harms a plaintiff ’s reputation by casting aspersions on its business, the plaintiff ’s injury flows directly from the audience’s belief in the disparaging statements.”  (Note that this discussion might seem to make the Lanham Act available to beef producers aggrieved by news stories about pink slime—but there “commercial advertising or promotion” will have to play the leading role.)

As a result, §43(a) is available not only when a product is denigrated by name, but also when “the defendant damages the product’s reputation by, for example, equating it with an inferior product.” (Citing false equivalency claims.) A defendant who “seeks to promote his own interests by telling a known falsehood to or about the plaintiff or his product” proximately caused the plaintiff ’s harm.  (Delete “known” for Lanham Act liability.) “[W]hen a party claims reputational injury from disparagement, competition is not required for proximate cause; and that is true even if the defendant’s aim was to harm its immediate competitors, and the plaintiff merely suffered collateral damage.”  A carmaker who disparages the airbags in a rival’s cars proximately harms both the rival carmaker and the airbag supplier.

Also, Static Control adequately alleged proximate cause by alleging that it made microchips that were necessary, and only useful for, refurbishing Lexmark cartridges.  Any false advertising that reduced the remanufacturers’ business therefore necessarily injured Static Control as well.  As alleged, “there is likely to be something very close to a 1:1 relationship between the number of refurbished Prebate cartridges sold (or not sold) by the remanufacturers and the number of Prebate microchips sold (or not sold) by Static Control.” Given such an integral injury, proximate cause would exist.  Sure, there’s an intervening link of injury to the remanufacturers, which might ordinarily destroy proximate cause, but that’s because there’s ordinarily a discontinuity between the injuries of the direct and indirect victims, such that injury to the latter might have resulted from any number of reasons.  Here, though, “Static Control’s allegations suggest that if the remanufacturers sold 10,000 fewer refurbished cartridges because of Lexmark’s false advertising, then it would follow more or less automatically that Static Control sold 10,000 fewer microchips for the same reason.”  This wouldn’t require speculative or uncertain inquiries. 

However, Static Control would ultimately have to show injury proximately caused by Lexmark’s alleged misrepresentations. It was just entitled to a chance to prove its case.

How will proximate cause work with “affiliation confusion,” I wonder?  Many judges, I expect, will continue to be sympathetic to trademark plaintiffs’ harm stories.  But if being in the zone of interests protected isn’t enough, and you also need proximately caused harm, that at least opens up some space to contest these trademark narratives.
Posted in http://schemas.google.com/blogger/2008/kind#post, standing | Leave a comment

ASA approves Microsoft’s ad accusing Gmail of creepy spying

Microsoft Corporation, No. A13-251580: Microsoft ran an ad beginning, “Ymay ivatepray e-mailway isway onway ofway eirthay usinessbay.” It continued: “Pig Latin may be hard to understand, but you probably need it if you use Gmail, because Gmail scans every word of your e-mails to sell ads. But Outlook.com doesn’t. And you can choose to opt out of personalised ads. To stop Gmail from using your e-mails, use Outlook.com. Learn more at KeepYourEmailPrivate.com and keep your e-mails ivatepray”.  Complainants challenged the ad because Microsoft scans email too. 

Microsoft rejoined that scanning email for ad targeting was different than standard scanning for viruses and spam, which consumers expect and which doesn’t involve data retention.  (What about scanning emails for trade secret leaks?)  The ASA agreed: the ad specifically mentioned scanning for ad targeting, rather than “protective” scanning, and consumers would perceive ad targeting as raising privacy issues (that, by implication, virus/spam scanning does not, though carried out through the same automated mechanisms).  Thus, the ad was not misleading.

Posted in advertising, http://schemas.google.com/blogger/2008/kind#post, privacy | Leave a comment

I feel so extraordinary: Lexmark affirmed

Here.  My first Supreme Court citation!  And approving, no less!  More later.

Posted in http://schemas.google.com/blogger/2008/kind#post, standing | Leave a comment